Microinjection of Reelin into the mPFC prevents MK-801-induced recognition memory impairment in mice

Masahito Sawahata1, Hiroki Asano2, Taku Nagai3

  • 1Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University, Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.

Pharmacological Research
|August 27, 2021
PubMed

Insights

Reelin protein administration into the medial prefrontal cortex (mPFC) in mice reversed MK-801-induced recognition memory deficits. This suggests Reelin

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Psychiatry

Background:

  • Reelin, an extracellular matrix protein, is crucial for neuronal plasticity and cognitive function.
  • Reelin dysfunction is linked to schizophrenia (SCZ).
  • Previous studies showed Reelin's potential in preventing certain behavioral deficits.

Purpose of the Study:

  • To investigate the therapeutic effect of Reelin on behavioral abnormalities in an animal model of schizophrenia.
  • To determine the neural mechanisms underlying Reelin's action in the medial prefrontal cortex (mPFC).

Main Methods:

  • Recombinant Reelin was microinjected into the mPFC of mice treated with MK-801, an NMDA receptor antagonist.
  • Behavioral tests included the novel object recognition test (NORT), pre-pulse inhibition, and Y-maze.
  • Neural activity was assessed by quantifying c-Fos-positive cells in the mPFC.
  • A Reelin mutant unable to bind its receptor was used to confirm the mechanism of action.

Main Results:

  • Reelin microinjection into the mPFC prevented MK-801-induced recognition memory impairment in the NORT.
  • Reelin did not affect MK-801-induced deficits in sensory-motor gating or short-term memory.
  • MK-801 increased c-Fos expression in the mPFC, which was suppressed by Reelin.
  • A non-receptor-binding Reelin mutant did not ameliorate cognitive deficits.

Conclusions:

  • Reelin administration into the mPFC can prevent specific cognitive deficits, such as recognition memory impairment, in an animal model of schizophrenia.
  • Reelin exerts its effects by binding to its receptors and modulating neural activity within the mPFC.
  • These findings highlight Reelin's potential as a therapeutic agent for cognitive dysfunction in schizophrenia.

Related Concept Videos